Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Total Liabilities for 16 consecutive years, with $338.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 3.71% to $338.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $338.6 million, a 3.71% increase, with the full-year FY2025 number at $338.6 million, up 3.71% from a year prior.
  • Total Liabilities was $338.6 million for Q4 2025 at Myriad Genetics, down from $355.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $465.7 million in Q3 2023 to a low of -$740.5 million in Q2 2024.
  • A 5-year average of $300.1 million and a median of $344.1 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 263.83% in 2024, then soared 139.05% in 2025.
  • Myriad Genetics' Total Liabilities stood at $352.9 million in 2021, then fell by 11.33% to $312.9 million in 2022, then rose by 16.11% to $363.3 million in 2023, then dropped by 10.13% to $326.5 million in 2024, then grew by 3.71% to $338.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Total Liabilities are $338.6 million (Q4 2025), $355.3 million (Q3 2025), and $289.2 million (Q2 2025).